@article{
author = "Nobili, Paola and SHEN, Weida and Milicevic, Katarina and Bogdanović Pristov, Jelena and Audinat, Etienne and Nikolic, Ljiljana",
year = "2022",
abstract = "Epilepsy and multiple sclerosis (MS), two of the most common neurological diseases, are
characterized by the establishment of inflammatory environment in the central nervous
system that drives disease progression and impacts on neurodegeneration. Current
therapeutic approaches in the treatments of epilepsy and MS are targeting neuronal
activity and immune cell response, respectively. However, the lack of fully efficient
responses to the available treatments obviously shows the need to search for novel
therapeutic candidates that will not exclusively target neurons or immune cells.
Accumulating knowledge on epilepsy and MS in humans and analysis of relevant
animal models, reveals that astrocytes are promising therapeutic candidates to target
as they participate in the modulation of the neuroinflammatory response in both diseases
from the initial stages and may play an important role in their development. Indeed,
astrocytes respond to reactive immune cells and contribute to the neuronal hyperactivity in
the inflamed brain. Mechanistically, these astrocytic cell to cell interactions are
fundamentally mediated by the purinergic signalling and involve metabotropic P2Y1
receptors in case of astrocyte interactions with neurons, while ionotropic P2X7
receptors are mainly involved in astrocyte interactions with autoreactive immune cells.
Herein, we review the potential of targeting astrocytic purinergic signalling mediated by
P2Y1 and P2X7 receptors to develop novel approaches for treatments of epilepsy and MS
at very early stages.",
publisher = "Frontiers Media",
journal = "Frontiers in Pharmacology",
title = "Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis",
pages = "900337",
volume = "13",
doi = "10.3389/fphar.2022.900337"
}
